Search

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
Route 79 Scholarship Program
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
SareptAssist Peer-to-Peer Program
SareptAssist Peer-to-Peer Program - Thank You
TERMS OF USE FOR SAREPTA THERAPEUTICS, INC.'S WEBSITES
SAREPTA WEBSITE PRIVACY POLICY
Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors
Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)